Sensitivity and resistance to DNA damage response inhibitors in acute myeloid leukemia with spliceosome mutations

Bidragets beskrivning

Acute myeloid leukemia (AML) is an aggressive blood cancer treated with combination chemotherapy. The development of therapy for AML has been slow, and the standard chemotherapy has remained unchanged for decades. Spliceosome mutations are recurrent drivers of AML pathogenesis. Recent research shows that spliceosome mutations induce a DNA damage response vulnerability that can be targeted therapeutically. This study identifies new drug sensitivities in spliceosome mutated AML.
Visa mer

Startår

2020

Slutår

2024

Beviljade finansiering

Samuli Eldfors Orcid -palvelun logo
297 957 €

Finansiär

Finlands Akademi

Typ av finansiering

Forskardoktorer

Övriga uppgifter

Finansieringsbeslutets nummer

334273

Vetenskapsområden

Biomedicinska vetenskaper

Forskningsområden

Biolääketieteet

Identifierade teman

cancer